Anteris Technologies Global CORP 8-K filings

Anteris Technologies Global Corp. announced that the Federal Court of Australia granted its application to rectify an administrative oversight concerning a late cleansing notice, leading to the lifting of a trading halt.

Anteris Technologies Global Corp. has requested a trading halt on its securities pending consideration of an inadvertent non-lodgement of cleansing notices for CHESS Depositary Interests.

Anteris Technologies Global Corp. has entered into a sales agreement with TD Securities (USA) LLC to offer and sell up to $250 million of its common stock through an at-the-market (ATM) program.

Anteris Technologies Global Corp. has elected to discontinue development contributions under a material agreement with v2vmedtech, inc., triggering a $400,000 break fee and potential equity adjustments.

Anteris Technologies Global Corp. has entered into a long-term lease agreement for a 181,436 square foot facility in Brooklyn Park, Minnesota.

Anteris Technologies Global Corp. reported a significant increase in net loss for 2025, alongside a 29% revenue decline, but secured $320 million in early 2026 capital raises and advanced its pivotal DurAVR THV trial.

Anteris Technologies Global Corp. announced a $90 million strategic investment from Medtronic plc and a combined $320 million capital raise to advance its DurAVR THV and PARADIGM trial.

Anteris Technologies Global Corp. announced a $320 million capital raise through a public offering and a strategic private placement with Medtronic plc, aimed at advancing its DurAVR THV pivotal trial and manufacturing capabilities.

Stephen Denaro has resigned from the Board of Directors of Anteris Technologies Global Corp., effective December 13, 2025, but will continue in other key roles.

Anteris Technologies Global Corp. stockholders approved all thirteen proposals at its Annual Meeting, including director elections, auditor appointment, and significant RSU grants to executives and directors.

Anteris Technologies Global Corp. announced the non-renewal of its supply and license agreement with 4C Medical Technologies, Inc., effective June 1, 2026, with no material financial impact.

Anteris Technologies announced positive 30-day clinical outcomes for its DurAVR Transcatheter Heart Valve in 100 severe aortic stenosis patients with small aortic annuli.

Anteris Technologies Global Corp. announced Q3 2025 financial results and significant regulatory progress for its DurAVR THV PARADIGM Trial in the US and Europe.

Anteris Technologies Global Corp. announced FDA approval to initiate its global pivotal trial, PARADIGM, for the DurAVR Transcatheter Heart Valve.

Anteris Technologies announced the successful enrollment and treatment of the first patients in its global pivotal PARADIGM Trial for the DurAVR Transcatheter Heart Valve.

Anteris Technologies Global Corp. successfully closed its Common Stock Offering, raising approximately US$11.5 million in gross proceeds.

Anteris Technologies Global Corp. secured approximately US$25 million in gross proceeds through an equity offering to fund its pivotal PARADIGM Trial for its biomimetic DurAVR THV.

Anteris Technologies Global Corp. announced the date for its inaugural Annual Meeting of Stockholders and the deadline for shareholder proposals.

Anteris Technologies Global Corp. announced its first European regulatory clearance from the Danish Medicines Agency to commence the DurAVR Transcatheter Heart Valve global pivotal trial.

Anteris Technologies Global Corp. stockholders approved an ASX waiver, while patient enrollment for its pivotal PARADIGM Trial is now expected in Q4 2025, a delay from Q3 2025.

Anteris Technologies Global Corp. has adjourned its Special Meeting of Stockholders due to a lack of quorum, rescheduling it for September 29, 2025.

Anteris Technologies Global Corp. announced the postponement of its Special Meeting of Stockholders to September 18, 2025, to allow for broader participation.

Anteris Technologies Global Corp. announced the postponement of its Special Meeting of Stockholders to September 11, 2025, to allow for broader participation.

Anteris Technologies Global Corp. reported increased losses and decreased revenue for the first half of 2025, while making significant clinical and operational progress on its DurAVR THV system and pivotal PARADIGM Trial.

Anteris Technologies Global Corp. has received an ongoing waiver from ASX Listing Rule 7.1, granting it greater flexibility for future securities issuance and capital raising without immediate shareholder approval.

Anteris Technologies Global Corp. has entered into a First Amended and Restated Master Services Agreement with Switchback Medical, LLC, securing ongoing development and manufacturing services until at least March 2028.

Anteris Technologies Global Corp. announced the appointment of Mr. Gregory Moss and Mr. David Roberts to its Board of Directors, alongside the resignation of Dr. Wenyi Gu, effective June 7, 2025.

Anteris Technologies reported its Q1 2025 financial results, highlighted by the IDE submission for the PARADIGM Trial and the treatment of over 100 patients with DurAVR THV.

Anteris Technologies announces a clinical milestone of treating over 100 patients worldwide with its DurAVR Transcatheter Heart Valve (THV).

Anteris Technologies announces favorable one-year patient outcomes for its DurAVR Transcatheter Heart Valve (THV), demonstrating sustained hemodynamic performance and zero prosthesis-patient mismatch (PPM) in small annuli patients.